Quick-Med receives patent for MultiStat technology to treat Rosacea

Quick-Med Technologies, Inc. (OTCBB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,795,302 entitled "Use of Compositions for Treating Rosacea." The patent is part of a portfolio that Quick-Med has licensed from the University of Michigan and extends the growing intellectual property coverage of the Company's MultiStat® family of compounds.

"This new patent covering methods for treating Rosacea with our MultiStat technology is yet another significant expansion that strengthens the IP estate under our licensing agreement with the University of Michigan," said J. Ladd Greeno, Quick-Med's CEO. "Although an estimated 16 million Americans currently suffer from rosacea, the treatments available today often create unwanted side effects, including skin redness and irritation. MultiStat is shown to promote the maintenance, healing and repair of the inflamed skin, and may be combined with existing medications to deliver more effective, better tolerated treatments."

The patent issued covers methods for treating rosacea with an antimicrobial, a retinoid, and an inhibitor of toll-like receptors in both topical and oral applications. The broad range of antimicrobials to be utilized in combination with the MultiStat family includes tetracycline, erythromycin, azithromycin, clarithromycin, milbemycin, aminoglycoside, penicillin (optimally in combination with a beta-lactamase inhibitor), cephalosporin, fluoroquinolone, streptogramin and sulfanomide.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Critical insights into COVID-19 exposure for healthcare workers